Clinical Research
Clinical Trial
One-Year Results of the SCORPIUS Study: A German Multicenter Investigation on the Effectiveness of Sirolimus-Eluting Stents in Diabetic Patients

https://doi.org/10.1016/j.jacc.2007.07.035Get rights and content
Under an Elsevier user license
open archive

Objectives

This study sought to analyze the effectiveness of drug-eluting stents in a high-risk group of diabetic patients. Previously, this had been analyzed only in substudies of larger trials or in clinical investigations enrolling a small number of patients.

Background

Drug-eluting stents are highly effective in reducing the rate of in-stent restenosis.

Methods

Two hundred patients with diabetes and de novo coronary artery lesions were enrolled in 16 centers: 98 were randomly assigned to sirolimus-eluting stents (SES) and 102 received bare-metal stents (BMS). The primary end point was in-segment late luminal loss. Major adverse cardiac events (MACE) rate was analyzed at 30 days and 8 and 12 months.

Results

The extent of in-segment late luminal loss in the SES group was 0.18 mm compared with 0.74 mm in the BMS group. In-segment restenosis was identified on follow-up angiography in 8.8% of the patients in SES and in 42.1% in BMS (p < 0.0001). Target lesion revascularization was performed in 5.3% of the patients in SES and in 21.1% of the patients in BMS (p = 0.002). The SES was effective in the treatment group with oral diabetic medication as well as in the insulin-dependent treatment group (3.6% SES vs. 38.8% BMS). There was no subacute stent thrombosis in the SES group up to 1 year. The MACE rate was not significantly different at 30 days. At 12 months, MACE rate was 14.7% in SES versus 35.8% in BMS.

Conclusions

The SES is safe and highly effective in patients with diabetes mellitus and coronary artery disease and associated with a significant decrease in the extent of late luminal loss.

Abbreviations and Acronyms

BMS
bare-metal stent(s)
CABG
coronary artery bypass graft
MACE
major adverse cardiac events
MLD
minimal luminal diameter
PCI
percutaneous coronary intervention
PTCA
percutaneous transluminal coronary angioplasty
SES
sirolimus-eluting stent(s)
TLR
target lesion revascularization

Cited by (0)

This study was initiated by the investigators and supported by a grant from Cordis, Johnson & Johnson, Langenfeld, Germany.